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Abstract
Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a mini-
mum of five effective rounds of mass drug administration (MDA) and demonstrating low
prevalence in subsequent assessments. The first assessments recommended by the World
Health Organization (WHO) are sentinel and spot-check sites—referred to as pre-transmis-
sion assessment surveys (pre-TAS)—in each implementation unit after MDA. If pre-TAS
shows that prevalence in each site has been lowered to less than 1% microfilaremia or less
than 2% antigenemia, the implementation unit conducts a TAS to determine whether MDA
can be stopped. Failure to pass pre-TAS means that further rounds of MDA are required.
This study aims to understand factors influencing pre-TAS results using existing program-
matic data from 554 implementation units, of which 74 (13%) failed, in 13 countries. Second-
ary data analysis was completed using existing data from Bangladesh, Benin, Burkina Faso,
Cameroon, Ghana, Haiti, Indonesia, Mali, Nepal, Niger, Sierra Leone, Tanzania, and
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Uganda. Additional covariate data were obtained from spatial raster data sets. Bivariate
analysis and multilinear regression were performed to establish potential relationships
between variables and the pre-TAS result. Higher baseline prevalence and lower elevation
were significant in the regression model. Variables statistically significantly associated with
failure (p-value�0.05) in the bivariate analyses included baseline prevalence at or above
5% or 10%, use of Filariasis Test Strips (FTS), primary vector of Culex, treatment with dieth-
ylcarbamazine-albendazole, higher elevation, higher population density, higher enhanced
vegetation index (EVI), higher annual rainfall, and 6 or more rounds of MDA. This paper
reports for the first time factors associated with pre-TAS results from a multi-country analy-
sis. This information can help countries more effectively forecast program activities, such as
the potential need for more rounds of MDA, and prioritize resources to ensure adequate cov-
erage of all persons in areas at highest risk of failing pre-TAS.
Author summary
Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a
minimum of five rounds of mass drug administration (MDA) and being able to demon-
strate low prevalence in several subsequent assessments. LF elimination programs imple-
ment sentinel and spot-check site assessments, called pre-TAS, to determine whether
districts are eligible to implement more rigorous population-based surveys to determine
whether MDA can be stopped or if further rounds are required. Reasons for failing pre-
TAS are not well understood and have not previously been examined with data compiled
from multiple countries. For this analysis, we analyzed data from routine USAID and
WHO reports from Bangladesh, Benin, Burkina Faso, Cameroon, Ghana, Haiti, Indone-
sia, Mali, Nepal, Niger, Sierra Leone, Tanzania, and Uganda. In a model that included
multiple variables, high baseline prevalence and lower elevation were significant. In mod-
els comparing only one variable to the outcome, the following were statistically signifi-
cantly associated with failure: higher baseline prevalence at or above 5% or 10%, use of the
FTS, primary vector of Culex, treatment with diethylcarbamazine-albendazole, lower ele-
vation, higher population density, higher Enhanced Vegetation Index, higher annual rain-
fall, and six or more rounds of mass drug administration. These results can help national
programs plan MDA more effectively, e.g., by focusing resources on areas with higher
baseline prevalence and/or lower elevation.
Introduction
Lymphatic filariasis (LF), a disease caused by parasitic worms transmitted to humans by mos-
quito bite, manifests in disabling and stigmatizing chronic conditions including lymphedema
and hydrocele. To eliminate LF as a public health problem, the World Health Organization
(WHO) recommends two strategies: reducing transmission through annual mass drug admin-
istration (MDA) and reducing suffering through ensuring the availability of morbidity man-
agement and disability prevention services to all patients [1]. For the first strategy, eliminating
LF as a public health problem is defined as a ‘reduction in measurable prevalence in infection
in endemic areas below a target threshold at which further transmission is considered unlikely
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even in the absence of MDA’ [2]. As of 2018, 14 countries have eliminated LF as a public health
problem while 58 countries remain endemic for LF [3].
The road to elimination as a public health problem has several milestones. First, where LF
prevalence at baseline has exceeded 1% as measured either through microfilaremia (Mf) or
antigenemia (Ag), MDA is implemented and treatment coverage is measured in all implemen-
tation units, which usually correspond to districts. Implementation units must complete at
least five rounds of ‘effective’ treatment, i.e. treatment with a minimum coverage of 65% of the
total population. Then, WHO recommends sentinel and spot-check site assessments—referred
to as pre-transmission assessment surveys (pre-TAS)—in each implementation unit to deter-
mine whether prevalence in each site is less than 1% Mf or less than 2% Ag [4]. Next, if these
thresholds are met, national programs can progress to the first transmission assessment survey
(TAS). The TAS is a population-based cluster or systematic survey of six- and seven-year-old
children to assess whether transmission has fallen below the threshold at which infection is
believed to persist. TAS is conducted at least three times, with two years between each survey.
TAS 1 results determine if it is appropriate to stop MDA or whether further rounds are
required. Finally, when TAS 2 and 3 also fall below the set threshold in every endemic imple-
mentation unit nationwide and morbidity criteria have been fulfilled, the national program
submits a dossier to WHO requesting that elimination be officially validated.
Pre-TAS include at least one sentinel and one spot-check site per one million population.
Sentinel sites are established at the start of the program in villages where LF prevalence was
believed to be relatively high. Spot-check sites are villages not previously tested but purposively
selected as potentially high-risk areas due to original high prevalence, low coverage during
MDA, high vector density, or other factors [4]. At least six months after MDA implementation,
data are collected from a convenience sample of at least 300 people over five years old in each
site. Originally, Mf was recommended as the indicator of choice for pre-TAS, assessed by
blood smears taken at the time of peak parasite periodicity [4]. WHO later recommended the
use of circulating filarial antigen rapid diagnostic tests, BinaxNow immunochromatographic
card tests (ICTs), and after 2016, Alere Filariasis Test Strips (FTS), because they are more sen-
sitive, easier to implement, and more flexible about time of day that blood can be taken [5].
When a country fails to meet the established thresholds in a pre-TAS, they must implement
at least two more rounds of MDA. National programs need to forecast areas that might fail
pre-TAS and need repeated MDA, so that they can inform the community and district deci-
sion-makers of the implications of pre-TAS failure, including the need for continued MDA to
lower prevalence effectively. In addition, financial and human resources must be made avail-
able for ordering drugs, distributing drugs, supervision and monitoring to implement the fur-
ther MDA rounds. Ordering drugs and providing MDA budgets often need to be completed
before the pre-TAS are implemented, so contingency planning and funding are important to
ensure rounds of MDA are not missed.
This study aims to understand which factors are associated with the need for additional
rounds of MDA as identified by pre-TAS results using programmatic data from 13 countries.
The factors associated with failing pre-TAS are not well understood and have not previously
been examined at a multi-country scale in the literature. We examine the association between
pre-TAS failure and baseline prevalence, parasites, environmental factors, MDA implementa-
tion, and pre-TAS implementation. Understanding determinants of pre-TAS failure will help
countries identify where elimination may be most difficult and prioritize the use of limited LF
elimination resources.
PLOS NEGLECTED TROPICAL DISEASES Risk factors associated with failing ‘pre-TAS’ in lymphatic filariasis programs
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008301 June 1, 2020 3 / 17
Methods
This is a secondary data analysis using existing data, collected for programmatic purposes.
Data for this analysis come from 568 districts in 13 countries whose LF elimination programs
were supported by the United States Agency for International Development (USAID) through
the ENVISION project, led by RTI International, and the END in Africa and END in Asia
projects, led by FHI 360. These countries are Bangladesh, Benin, Burkina Faso, Cameroon,
Ghana, Haiti, Indonesia, Mali, Nepal, Niger, Sierra Leone, Tanzania, and Uganda. The data
represent all pre-TAS funded by USAID from 2012 to 2017 and, in some cases, surveys funded
by host government or other non-United States government funders. Because pre-TAS data
were collected as part of routine program activities in most countries, in general, ethical clear-
ance was not sought for these surveys. Our secondary analysis only included the aggregated
survey results and therefore did not constitute human subjects research; no ethical approval
was required.
Building on previous work, we delineated five domains of variables that could influence
pre-TAS outcomes: prevalence, agent, environment, MDA, and pre-TAS implementation
(Table 1) [6–8]. We prioritized key concepts that could be measured through our data or cap-
tured through publicly available global geospatial data sets.
Data sources
Information on baseline prevalence, MDA coverage, the number of MDA rounds, and pre-
TAS information (month and year of survey, district, site name, and outcome) was gathered
through regular reporting for the USAID-funded NTD programs (ENVISION, END in Africa,
and END in Asia). These data were augmented by other reporting data such as the country’s
dossier data annexes, the WHO Preventive Chemotherapy and Transmission Control Data-
bank, and WHO reporting forms. Data were then reviewed by country experts, including the
Ministry of Health program staff and implementing program staff, and updated as necessary.
Data on vectors were also obtained from country experts. The district geographic boundaries
were matched to geospatial shapefiles from the ENVISION project geospatial data repository,
while other geospatial data were obtained through publicly available sources (Table 1).
Outcome and covariate variables
The outcome of interest for this analysis was whether a district passed or failed the pre-TAS.
Failure was defined as any district that had at least one sentinel or spot-check site with a preva-
lence higher than or equal to 1% Mf or 2% Ag [4].
Potential covariates were derived from the available data for each factor in the domain
groups listed in Table 1. New dichotomous variables were created for all variables that had
multiple categories or were continuous for ease of interpretation in models and use in program
decision-making. Cut-points for continuous variables were derived from either a priori knowl-
edge or through exploratory analysis considering the mean or median value of the dataset,
looking to create two groups of similar size with logical cut-points (e.g. rounding numbers to
whole numbers). All the variables derived from publicly available global spatial raster datasets
were summarized to the district level in ArcGIS Pro using the “zonal statistics” tool. The final
output used the continuous value measuring the mean pixel value for the district for all vari-
ables except geographic area. Categories for each variable were determined by selecting the
mean or median dataset value or cut-off used in other relevant literature [7]. The following
section describes the variables that were included in the final analysis and the final categoriza-
tions used.
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Baseline prevalence. Baseline prevalence can be assumed as a proxy for local transmission
conditions [14] and correlates with prevalence after MDA [14–20]. Baseline prevalence for
each district was measured by either blood smears to measure Mf or rapid diagnostic tests to
measure Ag. Other studies have modeled Mf and Ag prevalence separately, due to lack of a
standardized correlation between the two, especially at pre-MDA levels [21,22]. However,
because WHO mapping guidance states that MDA is required if either Mf or Ag is�1% and
there were not enough data to model each separately, we combined baseline prevalence values
regardless of diagnostic test used. We created two variables for use in the analysis (1) using the
cut-off of<5% or�5% (dataset median value of 5%) and (2) using the cut-off of<10% or
�10%.
Agent. In terms of differences in transmission dynamics by agent, research has shown
that Brugia spp. are more susceptible to the anti-filarial drug regimens than Wuchereria ban-
crofti parasites [23]. Thus, we combined districts reporting B. malayi and B. timori and com-
pared them to areas with W. bancrofti or mixed parasites. Two variables from other domains
Table 1. Categorization of potential factors influencing pre-TAS results.







Prevalence Baseline prevalence 5% cut off Maximum reported mapping or
baseline sentinel site prevalence
<5% Maximum Varies Programmatic
data
Prevalence Baseline prevalence 10% cut off Maximum reported mapping or
baseline sentinel site prevalence
<10% Maximum Varies Programmatic
data
Agent Parasite Parasite Predominate parasite in district W. bancrofti &
mixed
Binary value 2018 Programmatic
data
Environment Vector Vector Predominate vector in district Anopheles &
Mansonia
Binary value 2018 Country expert
Environment Geography Elevation Elevation measured in meters >350 Mean 2000 CGIAR-CSI
SRTM [9]




Environment Climate EVI Enhanced vegetation index > 0.3 Mean 2015 MODIS [10]
Environment Climate Rainfall Annual rainfall measured in
mm
� 700 Mean 2015 CHIRPS [11]
Environment Socio-economic Population density Number of people per km2 � 100 Mean 2015 WorldPop [12]
Environment Socio-economic Nighttime lights Nighttime light index from 0 to
63
>1.5 Mean 2015 VIIRS [13]
Environment Co-endemicity Co-endemic for
onchocerciasis
Part or all of district is also
endemic for onchocerciases
Non-endemic Binary value 2018 Programmatic
data




Coverage Median MDA coverage for last
5 rounds




Sufficient rounds Number of rounds of sufficient
(� 65% coverage) in last 5 years




Number of rounds Maximum number of recorded
rounds of MDA








Quality of survey Diagnostic test Using Mf, ICT, or FTS Mf Categorical Varies Programmatic
data
EVI = enhanced vegetation index; MDA = mass drug administration; TAS = transmission assessment survey; DEC = diethylcarbamazine; ALB = albendazole;
IVM = ivermectin; Mf = microfilaremia; Ag = antigenemia; FTS = Filariasis Test Strips; ICT = Immunochromatographic Card Test
https://doi.org/10.1371/journal.pntd.0008301.t001
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were identified in exploratory analyses to be highly colinear with the parasite, and thus we con-
sidered them in the same group of variables for the final regression models. These were vari-
ables delineating vectors (Anopheles or Mansonia compared to Culex) from the environmental
domain and drug package [ivermectin-albendazole (IVM-ALB) compared to diethylcarbama-
zine-albendazole (DEC-ALB)] from the MDA domain.
Environment. LF transmission intensity is influenced by differing vector transmission
dynamics, including vector biting rates and competence, and the number of individuals with
microfilaria [21,24,25]. Since vector data are not always available, previous studies have
explored whether environmental variables associated with vector density, such as elevation,
rainfall, and temperature, can be used to predict LF prevalence [8,21,26–31]. We included the
district area and elevation in meters as geographic variables potentially associated with trans-
mission intensity. In addition, within the climate factor, we included Enhanced Vegetation
Index (EVI) and rainfall variables. EVI measures vegetation levels, or “greenness,” where a
higher index value indicates a higher level of “greenness.”
We included the socio-economic variable of population density, as it has been positively
associated with LF prevalence in some studies [8,27,29], but no significant association has
been found in others [30]. Population density could be correlated with vector, as in eastern
African countries LF is mostly transmitted by Culex in urban areas and by Anopheles in rural
areas [32]. Additionally, inclusion of the satellite imagery of nighttime lights data is another a
proxy for socio-economic status [33].
Finally, all or parts of districts that are co-endemic with onchocerciasis may have received
multiple rounds of MDA with ivermectin before LF MDA started, which may have lowered LF
prevalence in an area [34–36]. Thus, we included a categorical variable to distinguish if dis-
tricts were co-endemic with onchocerciasis.
MDA. Treatment effectiveness depends upon both drug efficacy (ability to kill adult
worms, ability to kill Mf, drug resistance, drug quality) and implementation of MDA (cover-
age, compliance, number of rounds) [14,16]. Ivermectin is less effective against adult worms
than DEC, and therefore it is likely that Ag reduction is slower in areas using ivermectin
instead of DEC in MDA [37]. Models also have shown that MDA coverage affects prevalence,
although coverage has been defined in various ways, such as median coverage, number of
rounds, or individual compliance [14–16,20,38–40]. Furthermore, systematic non-compliance,
or population sub-groups which consistently refuse to take medicines, has been shown to rep-
resent a threat to elimination [41,42].
We considered three approaches when analyzing the MDA data: median MDA coverage in
the most recent 5 rounds, number of rounds with sufficient coverage in the most recent 5
rounds, and count of the total number of rounds. MDA coverage is considered sufficient at or
above 65% of the total population who were reported to have ingested the drugs; this was used
as the cut point for MDA median coverage for the most recent 5 rounds. The ‘rounds of suffi-
cient coverage’ variable was categorized as having 2 or fewer rounds compared to 3 or more
sufficient rounds. The ‘total number of MDA rounds’ variable was categorized at 5 or fewer
rounds compared to 6 or more rounds ever documented in that district.
Pre-TAS implementation. Pre-TAS results can be influenced by the implementation of
the survey itself, including the use of a particular diagnostic test, the selection of sites, the tim-
ing of survey, and the appropriate application of methods for population recruitment and
diagnostic test adminstration. We included two variables in the pre-TAS implementation
domain: ‘type of diagnostic method used’ and ‘diagnostic test used.’ The ‘type of diagnostic
method used’ variable categorized districts by either using Mf or Ag. The ‘diagnostic test used’
variable examined Mf (reference category) compared to ICT and compared to FTS (categorical
variable with 3 values). This approach was used to compare each test to each other. Countries
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switched from ICT to FTS during 2016, while Mf testing continued to be used throughout the
time period of study.
Data inclusion criteria
The dataset, summarized at the district level, included information from 568 districts where
a pre-TAS was being implemented for the first time. A total of 14 districts were removed
from the final analysis due to missing data related to the following points: geospatial bound-
aries (4), baseline prevalence (4), and MDA coverage (6). The final analysis dataset had 554
districts.
Statistical analysis and modeling
Statistical analysis and modeling were done with Stata MP 15.1 (College Station, TX). Descrip-
tive statistics comparing various variables to the principle outcome were performed. Signifi-
cant differences were identified using a chi-square test. A generalized linear model (GLM)
with a log link and binomial error distribution—which estimates relative risks—was developed
using forward stepwise modeling methods (called log-binomial model). Models with higher
pseudo-r-squared and lower Akaike information criterion (AIC) were retained at each step.
Pseudo-r-squared is a value between 0 and 1 with the higher the value, the better the model is
at predicting the outcome of interest. AIC values are used to compare the relative quality of
models compared to each other; in general, a lower value indicates a better model. Variables
were tested by factor group. Once a variable was selected from the group, no other variable in
that same group was eligible to be included in the final model due to issues of collinearity and
small sample sizes. Interaction between terms in the model was tested after model selection,
and interaction terms that modified the original terms’ significance were included in the final
model. Overall, the number of potential variables able to be included in the model remained
low due to the relatively small number of failure results (13%) in the dataset. Furthermore, the
models with more than 3 variables and one interaction term either were unstable (indicated by
very large confidence interval widths) or did not improve the model by being significant pre-
dictors or by modifying other parameters already in the model. These models were at height-
ened risk of non-convergence; we limited the number of variables accordingly.
Sensitivity analysis was performed for the final log-binomial model to test for the validity of
results under different parameters by excluding some sub-sets of districts from the dataset and
rerunning the model. This analysis was done to understand the robustness of the model when
(1) excluding all districts in Cameroon, (2) including only districts in Africa, (3) including
only districts with W. bancrofti parasite, and (4) including only districts with Anopheles as the
primary vector. The sensitivity analysis excluding Cameroon was done for two reasons. First,
Cameroon had the most pre-TAS results included, but no failures. Second, 70% of the Camer-
oon districts included in the analysis are co-endemic for loiasis. Given that diagnostic tests
used in LF mapping have since been shown to cross-react with loiasis, there is some concern
that these districts might not have been truly LF-endemic [43,44].
Results
The overall pre-TAS pass rate for the districts included in this analysis was 87% (74 failures in
554 districts). Nearly 40% of the 554 districts were from Cameroon (134) and Tanzania (87)
(Fig 1). No districts in Bangladesh, Cameroon, Mali, or Uganda failed a pre-TAS in this data
set; over 25% of districts in Burkina Faso, Ghana, Haiti, Nepal, and Sierra Leone failed pre-
TAS in this data set. Baseline prevalence varied widely within and between the 13 countries.
Fig 2 shows the highest, lowest, and median baseline prevalence in the study districts by
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Fig 1. Number of pre-TAS by country.
https://doi.org/10.1371/journal.pntd.0008301.g001
Fig 2. District-level baseline prevalence by country.
https://doi.org/10.1371/journal.pntd.0008301.g002
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country. Burkina Faso had the highest median baseline prevalence at 52% and Burkina Faso,
Tanzania, and Ghana all had at least one district with a very high baseline of over 70%. In
Mali, Indonesia, Benin, and Bangladesh, all districts had baseline prevalences below 20%.
Fig 3 shows the unadjusted analysis for key variables by pre-TAS result. Variables statisti-
cally significantly associated with failure (p-value�0.05) included higher baseline prevalence
at or above 5% or 10%, FTS diagnostic test, primary vector of Culex, treatment with DEC-ALB,
higher elevation, higher population density, higher EVI, higher annual rainfall, and six or
more rounds of MDA. Variables that were not significantly associated with pre-TAS failure
included diagnostic method used (Ag or Mf), parasite, co-endemicity for onchocerciasis,
median MDA coverage, and sufficient rounds of MDA.
The final log-binomial model included the variables of baseline prevalence�10%, the diag-
nostic test used (FTS and ICT), and elevation. The final model also included a significant inter-
action term between high baseline and diagnostic test used.
Fig 4 shows the risk ratio results with their corresponding confidence intervals. In a model
with interaction between baseline and diagnostic test the baseline parameter was significant
while diagnostic test and the interaction term were not. Districts with high baseline had a sta-
tistically significant (p-value�0.05) 2.52 times higher risk of failure (95% CI 1.37–4.64) com-
pared to those with low baseline prevalence. The FTS diagnostic test or ICT diagnostic test
alone were not significant nor was the interaction term. Additionally, districts with an eleva-
tion below 350 meters had a statistically significant (p-value�0.05) 3.07 times higher risk of
failing pre-TAS (95% CI 1.95–4.83).
Sensitivity analyses were conducted using the same model with different subsets of the data-
set including (1) all districts except for districts in Cameroon (134 total with no failures), (2)
only districts in Africa, (3) only districts with W. bancrofti, and (4) only districts with Anophe-
les as primary vector. The results of the sensitivity models (Table 2) indicate an overall robust
model. High baseline and lower elevation remained significant across all the models. The ICT
diagnostic test used remains insignificant across all models. The FTS diagnostic test was posi-
tively significant in model 1 and negatively significant in model 4. The interaction term of
baseline prevalence and FTS diagnostic test was significant in three models though the esti-
mate was unstable in the W. bancrofti-only and Anopheles-only models (models 3 and 4
respectively), as signified by large confidence intervals.
Overall 74 districts in the dataset failed pre-TAS. Fig 5 summarizes the likelihood of failure
by variable combinations identified in the log-binomial model. For those districts with a base-
line prevalence�10% that used a FTS diagnostic test and have an average elevation below 350
meters (Combination C01), 87% of the 23 districts failed. Of districts with high baseline that
used an ICT diagnostic test and have a low average elevation (C02) 45% failed. Overall, combi-
nations with high baseline and low elevation C01, C02, and C04 accounted for 51% of all the
failures (38 of 74).
Discussion
This paper reports for the first time factors associated with pre-TAS results from a multi-coun-
try analysis. Variables significantly associated with failure were higher baseline prevalence and
lower elevation. Districts with a baseline prevalence of 10% or more were at 2.52 times higher
risk to fail pre-TAS in the final log-binomial model. In the bivariate analysis, baseline preva-
lence above 5% was also significantly more likely to fail compared to lower baselines, which
indicates that the threshold for higher baseline prevalence may be as little as 5%, similar to
what was found in Goldberg et al., which explored ecological and socioeconomic factors asso-
ciated with TAS failure [7].
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Fig 3. Percent pre-TAS failure by each characteristic (unadjusted).
https://doi.org/10.1371/journal.pntd.0008301.g003
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Fig 4. Adjusted risk ratios for pre-TAS failure with 95% Confidence Interval from log-binomial model.
https://doi.org/10.1371/journal.pntd.0008301.g004
Table 2. Adjusted risk ratios for pre-TAS failure from log-binomial model sensitivity analysis.
(1) (2) (3) (4)








Number of Failures 74 74 44 72 46
Number of total districts (N = 554) (N = 420) (N = 407) (N = 518) (N = 414)
Covariate RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)




1.23 (0.52–2.92) 14.52 (1.79–117.82) 2.61 (1.03–6.61) 15.80 (1.95–127.67)




0.42 (0.11–1.68) 1.00 (0.00–0.00) 0.88 (0.21–3.60) 1.00 (0.00–0.00)
+Used FTS test 1.16 (0.52–
2.59)
2.40 (1.12–5.11) 0.15 (0.02–1.11) 1.03 (0.45–2.36) 0.13 (0.02–0.96)
+Used ICT test 0.92 (0.32–
2.67)
1.47 (0.51–4.21) 0.33 (0.04–2.54) 0.82 (0.28–2.43) 0.27 (0.03–2.04)
+Baseline prevalence> = 10% 2.52 (1.37–
4.64)
2.42 (1.31–4.47) 2.03 (1.06–3.90) 2.30 (1.21–4.36) 2.01 (1.07–3.77)
Elevation < 350m 3.07 (1.95–
4.83)
2.21 (1.42–3.43) 4.68 (2.22–9.87) 3.04 (1.93–4.79) 3.76 (1.92–7.37)
NOTE: Table shows adjusted Risk Ratio (RR) of failing pre-TAS.
Gray shading & + denote interaction terms, Bold text denotes statistically significant results with p-values�0.05
https://doi.org/10.1371/journal.pntd.0008301.t002
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Though diagnostic test used was selected for the final log-binomial model, neither category
(FTS or ICT) were significant after interaction with high baseline. FTS alone is significant in
the bivariate analysis compared to ICT or Mf. This result is not surprising given previous
research which found that FTS was more sensitive than ICT [45].
Elevation was the only environmental domain variable selected for the final log-binomial
model during the model selection process, with areas of lower elevation (<350m) found to be
at 3.07 times higher risk to fail pre-TAS compared to districts with a higher elevation. Similar
results related to elevation were found in previous studies [8,31], including Goldberg et al. [7],
who used a cutoff of 200 meters. Elevation likely also encompasses some related environmental
concepts, such as vector habitat, greenness (EVI), or rainfall, which impact vector chances of
survival.
The small number of failures overall prevented the inclusion of a large number of variables
in the final log-binomial model. However, other variables that are associated with failure as
identified in the bivariate analyses, such as Culex vector, higher population density, higher
EVI, higher rainfall and more rounds of MDA, should not be discounted when making pro-
grammatic decisions. Other models have shown that Culex as the predominant vector in a dis-
trict, compared to Anopheles, results in more intense interventions needed to reach
elimination [24,41]. Higher population density, which was also found to predict TAS failure
[7], could be related to different vector species’ transmission dynamics in urban areas, as well
as the fact that MDAs are harder to conduct and to accurately measure in urban areas [46,47].
Both higher enhanced vegetation index (>0.3) and higher rainfall (>700 mm per year)
Fig 5. Analysis of failures by model combinations.
https://doi.org/10.1371/journal.pntd.0008301.g005
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contribute to expansion of vector habitats and population. Additionally, having more than five
rounds of MDA before pre-TAS was also statistically significantly associated with higher fail-
ure in the bivariate analysis. It is unclear why higher number of rounds is associated with first
pre-TAS failure given that other research has shown the opposite [15,16].
All other variables included in this analysis were not significantly associated with pre-TAS
failure in our analysis. Goldberg et al. found Brugia spp. to be significantly associated with fail-
ure, but our results did not. This is likely due in part to the small number of districts with Bru-
gia spp. in our dataset (6%) compared to 46% in the Goldberg et al. article [7]. MDA coverage
levels were not significantly associated with pre-TAS failure, likely due to the lack of variance
in the coverage data since WHO guidance dictates a minimum of five rounds of MDA with
�65% epidemiological coverage to be eligible to implement pre-TAS. It should not be inter-
preted as evidence that high MDA coverage levels are not necessary to lower prevalence.
Limitations to this study include data sources, excluded data, unreported data, misassigned
data, and aggregation of results at the district level. The main data sources for this analysis
were programmatic data, which may be less accurate than data collected specifically for
research purposes. This is particularly true of the MDA coverage data, where some countries
report data quality challenges in areas of instability or frequent population migration. Even
though risk factors such as age, sex, compliance with MDA, and use of bednets have been
shown to influence infection in individuals [40,48–50], we could not include factors from the
human host domain in our analysis, as data sets were aggregated at site level and did not
include individual information. In addition, vector control data were not universally available
across the 13 countries and thus were not included in the analysis, despite studies showing that
vector control has an impact on reducing LF prevalence [41,48,51–53].
Fourteen districts were excluded from the analysis because we were not able to obtain com-
plete data for baseline prevalence, MDA coverage, or geographic boundaries. One of these dis-
tricts had failed pre-TAS. It is likely these exclusions had minimal impact on the conclusions,
as they represented a small number of districts and were similar to other included districts in
terms of key variables. Unreported data could have occurred if a country conducted a pre-TAS
that failed and then chose not to report it or reported it as a mid-term survey instead. Anec-
dotally, we know this has occurred occasionally, but we do not believe the practice to be wide-
spread. Another limitation in the analysis is a potential misassignment of key variable values to
a district due to changes in the district over time. Redistricting, changes in district size or com-
position, was pervasive in many countries during the study period; however, we expect the
impact on the study outcome to be minimal, as the historical prevalence and MDA data from
the “mother” districts are usually flowed down to these new “daughter” districts. However, it is
possible that the split created an area of higher prevalence or lower MDA coverage than would
have been found on average in the overall larger original “mother” district. Finally, the aggre-
gation or averaging of results to the district level may mask heterogeneity within districts.
Though this impact could be substantial in districts with considerable heterogeneity, the use of
median values and binomial variables mitigated the likelihood of skewing the data to extreme
outliners in a district.
As this analysis used data across a variety of countries and epidemiological situations, the
results are likely relevant for other districts in the countries examined and in countries with
similar epidemiological backgrounds. In general, as more data become available at site level
through the increased use of electronic data collection tools, further analysis of geospatial vari-
ables and associations will be possible. For example, with the availability of GPS coordinates, it
may become possible to analyze outcomes by site and to link the geospatial environmental
domain variables at a smaller scale. Future analyses also might seek to include information
from coverage surveys or qualitative research studies on vector control interventions such as
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bed net usage, MDA compliance, population movement, and sub-populations that might be
missed during MDA. Future pre-TAS using electronic data collection could include sex and
age of individuals included in the survey.
This paper provides evidence from analysis of 554 districts and 13 countries on the factors
associated with pre-TAS results. Baseline prevalence, elevation, vector, population density,
EVI, rainfall, and number of MDA rounds were all significant in either bivariate or multivari-
ate analyses. This information along with knowledge of local context can help countries more
effectively plan pre-TAS and forecast program activities, such as the potential need for more
than five rounds of MDA in areas with high baseline and/or low elevation.
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